Table I.

Participant demographics

Group	ID	Age, years	Sex	Neurological injury level	AIS	Time post-injury, years	Prescription medications	Eligibility
Ekso	EK01a	42	Male	T3	A	24	None	NDO
	EK02	30	Male	C5	B	1	Baclofen, Tizanidine	NDO, FC
	EK03	24	Male	T8	A	2	None	NDO
Loko	LK01	26	Male	T5	A	3	Gabapentin, Baclofen, Oxycodone, Nortriptyline, Mirabegron	UI, NDO
	LK02	49	Male	T6	B	< 1b	Gabapentin	UI, FC, NDO

The participant characteristics for each person that completed at minimum the training intervention. AIS: American Spinal Injury Association Impairment Scale, where A=motor and sensory complete, and B=motor complete and sensory incomplete; Eligibility=neurogenic lower urinary tract dysfunction present at intake including NDO: neurogenic detrusor overactivity; UI: urinary incontinence, or FC: frequent catheterization (less than 4 h on average).

^aunable to complete the post-training assessments.

^bLK02 was 7 months post-injury at enrolment in the trial.